SingleCell Biotechnology, has developed a breakthrough platform to stop the recurrence of cancer.
Our platform helps clinicians and drug companies assess underlying cells responsible for recurrence so that new drugs and treatments can be realized.
SingleCell Biotechnology, has developed a breakthrough platform to stop the recurrence of cancer.
Our platform helps clinicians and drug companies assess underlying cells responsible for recurrence so that new drugs and treatments can be realized.
Cancer recurrence is responsible for far too many cancer deaths due to the resistant and aggressive behavior of recurring cancer. Current drug development models utilize cancer information based on the primary tumor but contain very little, if any, information with regard to cancer stem cells responsible for recurrence. We need a way to test and treat cancer stem cells responsible for recurrence in order to provide better information about patient tumors AND to develop new drugs to combat recurrence.
Awarded Rising Star at BioNTX IC3 Conference
Awarded CPRIT SEED Grant ($2.5M) to optimize assays and demonstrate usefulness in drug development for GBM.
Successfully tested on primary patient GBM tumor cells direct from the operating room to demonstrate use as a personalized diagnostic device.
Platform successfully tested on Glioblastoma (brain) cancer AND breast cancer PDX cell lines to demonstrate usefulness as a drug discovery tool.
Used platform to demonstrate effectiveness (or non-effectiveness) of current drugs and radiation on dormant and migrating cells.
Demonstrated use case of a repurposed drug using the platform.
Prototype stage completed
Senior Scientist Data Engineer
Awarded CPRIT Grant for $2.5M to further the optimization of the plaform assays and demonstrate drug development in finding new biomarkers to combat difficult cancers.
Platform successfully tested with primary tumor cells direct from operating room to show that it has the ability to be used as a diagnostic device.
4 well device version of platform devices made ready for production, past the prototype stage.
Demonstrated that the platform can be used to identify re-purposed drugs that can be used to enhance or provide improved treatment outcomes.
Used platform to demonstrate how current drugs and radiation have little to no effect on migrating and dormant cancer cells. Further showing that current treatments targeting rapidly dividing cells leave this lethal population of non-dividing cells behind.
Platform successfully demonstrated on prototype devices to demonstrate single cell dormancy, migration, and clonogenic assays with both Glioblastoma (brain) cancer and breast cancer patient derived cell lines.
SingleCell Biotechnology selected to receive CPRIT Grant Award for $2.5M to further develop their ground breaking assays and demonstrate their usefulness in drug development.
